BACKGROUND: There is growing evidence that blood transfusion is associated with clinical factors that can lead to transfusion-induced immunosuppression. This effect can be beneficial or deleterious. METHODS: The effect of perioperative allogeneic blood transfusion on survival was studied retrospectively in 524 @entity1 who were discharged from the hospital after esophagogastrectomy for @entity189 performed in a single unit over a 10-year period. RESULTS: The median operative @entity190 for the series was 500 mL (range, 50 to 3,750 mL). Three hundred thirty-five @entity1 (64%) received a perioperative allogeneic blood transfusion related to esophagogastrectomy, and 189 (36%) did not. The median perioperative blood transfusion administered was 900 mL (range, 300 to 12,950 mL). Perioperative allogeneic blood transfusion was associated with reduced survival for @entity1 in stage III (p < 0.05) at 1 year, but no significant difference was found in this stage at 3 or 5 years after resection. Stage III disease accounted for 250 (48%) of the 524 @entity1 discharged. CONCLUSIONS: Although perioperative allogeneic blood transfusion does not affect long-term survival after esophagogastrectomy for @entity189 , it does have a significant association with short-term survival in a group whose overall survival is often limited after resection. Attention should be directed toward minimizing operative @entity190 and transfusing only for factors known to be clinically important, such as @entity26 delivery and hemodynamics, not arbitrary hemoglobin levels.

Effect of blood transfusion on survival after esophagogastrectomy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']
@entity189 :: (MESH:D002277,Disease) :: ['carcinoma']
